Climb Bio Reports First Patient Dosed in Phase 2 IgA Nephropathy Trial

What Happened
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced dosing of the first patient in a Phase 2 clinical trial for immunoglobulin A (IgA) nephropathy in China. The trial is being conducted in collaboration with Climb Bio, Inc.; Climb Bio disclosed the announcement in an 8-K filed August 14, 2026.

Key Details

• Announcement date: August 13, 2026 (Beijing Mabworks); 8-K filed by Climb Bio on August 14, 2026.
• Sponsor/partner: Beijing Mabworks Biotech Co., Ltd., collaborating with Climb Bio, Inc.
• Program: Phase 2 clinical trial in China for immunoglobulin A (IgA) nephropathy.
• Milestone: First patient dosed (no safety or efficacy results reported in the filing).

Why It Matters
This is a development milestone for Climb Bio’s collaboration with Mabworks showing active progress in the company’s clinical pipeline. For investors, a "first patient dosed" is an operational update that can mark the start of a trial stage potentially leading to future data readouts; however, the filing does not include trial results or timelines for next milestones. Investors should view this as a confirmation of ongoing clinical activity rather than evidence of efficacy or safety outcomes.